← All trials
NCT04971473
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Jul 31, 2023
- First posted
- Jul 21, 2021
- Last posted
- Dec 1, 2021
- Enrollment
- 201
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Suzhou Zelgen Biopharmaceuticals Co.,LtdLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.